The relevant passage is below. Basically it's a funnel, so It takes testing a large amount of people to tease out just a handful of infections. 162 cases for p

The relevant passage is below. Basically it's a funnel, so It takes testing a large amount of people to tease out just a handful of infections. 162 cases for placebo vs. 8 in the vaccine group. Analysis of the data indicates a vaccine efficacy rate of 95% (p<0.0001) in participants without prior SARS-CoV-2 infection (first primary objective) and also in participants with and without prior SARS-CoV-2 infection (second primary objective), in each case measured from 7 days after the second dose. The first primary objective analysis is based on 170 cases of COVID-19, as specified in the study protocol, of which 162 cases of COVID-19 were observed in the placebo group versus 8 cases in the BNT162b2 group. Efficacy was consistent across age, gender, race and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94%.